We provided an update on biosimilars: Health Canada's guidance, approvals and reviews of biosimilars to date, the effect of CETA amendments to biologics, pending patent litigation involving biosimilars, and pricing and reimbursement of biosimilars. Health Canada approved two biosimilars in 2017: ERELZI (Sandoz's etanercept) and RENFLEXIS (Samsung Bioepis' infliximab).
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
